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Background. The role of Aeromonas species (sp.) in bacteremia in Japanese patients with liver cirrhosis is poorly understood.
Aim. To establish the importance of Aeromonas sp. as a cause of bacteremia in patients with liver cirrhosis. Methods. Clinical and
serological features and short-term prognosis were retrospectively investigated and compared in Japanese patients with bacteremia
due to Aeromonas sp. (n = 11) and due to enterobacteria (E. coli, Klebsiella sp., and Enterobacter sp.) (n = 84). Results. There were
no signiﬁcant diﬀerences in patients’ clinical background, renal dysfunction, or short-term mortality rate between the two groups.
However, in the Aeromonas group, the model for end-stage liver disease (MELD) score and Child-Pugh score were signiﬁcantly
higher than in the enterobacteria group. Conclusion. These results indicate that the severity of liver dysfunction in Aeromonas-
induced bacteremia is greater than that in enterobacteria-induced bacteremia in Japanese patients with liver cirrhosis.
1.Introduction
The widespread use of cephem antibiotics and the increase
in the number of patients with indwelling catheters have led
to an increase in the proportion of Gram-positive bacteria
among pathogenic bacteria causing bacteremia in hospital-
ized patients in Japan since the early 1980s [1]. Nevertheless,
Gram-negative bacteria, including enterobacteria such as E.
coli and Klebsiella sp., are still the most important causes
of bacteremia in liver cirrhosis patients [1–5]. However, the
source of infection is often unknown in bacteremia of liver
cirrhotic patients, and the pathogenic bacteria can rarely
be identiﬁed from clinical ﬁndings alone. There has been
no previous report of a comparative study on the roles
of Aeromonas sp. a n do t h e rb a c t e r i ai nb a c t e r e m i ao fl i v e r
cirrhosis patients. Therefore, we conducted a retrospective
study of liver cirrhotic patients in Japan to examine the im-
portance of Aeromonas as a cause of bacteremia, compared
with enterobacteria (E. coli, Klebsiella sp., and Enterobacter
sp.).
2.MaterialsandMethods
2.1. Subjects and Methods. The subjects of this study were
patients hospitalized for liver cirrhosis in the Depart-
ment of Gastroenterology, Tokyo Women’s Medical College,
Tokyo (1991–2003), Nagashio Hospital, Tokyo (1996–2004),
Kikuna Memorial Hospital, Kanagawa (2007–2009), or the
Department of Gastroenterology, International University of
Health and Welfare Hospital, Tochigi (2007–2010), all of
which are located in the Kanto district of Japan.
Patients with bacteremia were included in this study,
regardless of whether or not septicemia was present. Patients
whose blood cultures showed multiple types of bacteria were
excluded from the study. For blood culture, one or several
samples of venous or arterial blood had been aseptically col-
lected and inoculated into aerobic (BACTEC Plus Aerobic/F
Culture Vial) and anaerobic (BACTEC Plus Anaerobic/F
Culture Vial) culture bottles. Culture was conducted with
shakingforsevendaysusingadedicatedbloodculturesystem
(Becton, Dickinson Co., USA).2 Gastroenterology Research and Practice
Table 1: Microorganisms isolated from blood cultures in patients
with liver cirrhosis.
Microorganisms Number %
Gram-positive bacteria 76 36.7%
MRSA 29 14.0%
MSSA 21 10.1%
Staphylococcus epidermidis 10 4.8%
Enterococcus sp. 73 . 4 %
Streptococcus sp. 52 . 4 %
Others 4 1.9%
Gram-negative bacteria 123 59.4%
Escherichia coli 44 21.3%
Klebsiella sp. 37 17.9%
Pseudomonas sp. 19 9.2%
Aeromonas sp. 11 5.3%
Enterobacter sp. 52 . 4 %
Others 7 3.4%
Others 8 3.9%
Total 207 100%
MRSA: methicillin resistant Staphylococcus aureus.
MSSA: methicillin sensitive Staphylococcus aureus.
Patients with diagnoses of spontaneous bacterial peri-
tonitis (SBP), infectious pleural eﬀusion, peritonitis carci-
nomatosa, and hemorrhagic ascites, such as hepatocellular
carcinoma rupture, were also excluded from the study. SBP
was diagnosed regardless of the presence of bacteria in the
ascitic ﬂuid in cases where the neutrophil count in ascitic
ﬂuid was 500/mm3or more. In cases having subjective and
objective symptoms of SBP, a neutrophil count between
250/mm3 and 500/mm3 was considered suﬃcient [6].
Patients whose blood cultures were positive for any
of E. coli, Klebsiella sp., or Enterobacter sp. were assigned
to the enterobacterial bacteremia group, and those blood
cultures were positive for Aeromonas sp. were assigned to the
Aeromonas bacteremia group. Patients’ backgrounds, clinical
and serological ﬁndings, and short-term (within one month)
prognoses were compared between the two groups. Hema-
tological test data including the MELD score and Child-
Pugh score obtained at the time of blood culture are expres-
sed as mean ± standard deviation (SD).
2.2. Statistical Analysis. Statistical analysis as conducted us-
ing an unpaired t-test to compare the ages of patients and
hematological test data in the two groups, and a contingency
tablewasusedtocompareratiosinpatients’backgroundfac-
tors and mortality rates. Diﬀerences were considered signiﬁ-
cant at the level of P<0.05 in all statistical analysis.
3. Results
3.1. Rates of Pathogenic Bacteria in Bacteremia. Among the
liver cirrhosis patients with bacteremia in this study, 21.3%
(44/207) showed blood cultures positive for E. coli, 17.9%
(37/207) for Klebsiella sp., 2.4% (5/207) for Enterobacter sp.,
and 5.3% (11/207) for Aeromonas sp. (Table 1). Excluding
two cases in which multiple bacteria were detected, we
obtained 84 cases involving enterobacteria (43 E. coli,3 6
Klebsiella sp., and 5 Enterobacter sp.), and 11 cases involving
Aeromonas sp.
3.2. Species and Onset Period of Bacteremia due to Aeromonas.
There were 9 cases in which A. hydrophila was detected and 2
cases in which A. veronii biovar sobria (identiﬁed as A. sobria
at the time) was detected. Of these 11 cases, 4 cases had a
summer onset (June through August), while 3 had a winter
onset (December through February). None of the patients
involved was known to have eaten raw ﬁsh.
3.3. Comparison of Background Factors and Clinical Findings
in the Two Groups. No signiﬁcant diﬀerence was observed in
the backgrounds of the two groups, including age, presence
or absence of hepatocellular carcinoma or diabetes mellitus,
occurrence of ascites or acute diarrhea, frequency of shocks,
rate of complication with SBP, or history of gastrointestinal
hemorrhage within two weeks of onset (Table 2). Moreover,
no patients with prior episodes of cholecystitis were present
in the Aeromonas bacteremia group in this study, although 2
out of 11 had gallstones.
3.4. Comparison of Hematological Test Data in the Two
Groups. The Child-Pugh score was signiﬁcantly (P<0.01)
higher in the Aeromonas bacteremia group (13.3 ±0.81) ver-
sus the enterobacterial bacteremia group (11.2 ± 1.93). The
MELD score [7] was also signiﬁcantly (P<0.01) higher
in the Aeromonas bacteremia group (26.1 ± 1.86) versus
the enterobacterial bacteremia group (21.9 ± 2.22). The two
groups showed no signiﬁcant diﬀerence in albumin levels,
ammonia levels, BUN levels, or creatinine levels (Table 3).
3.5. Comparison of Short-Term Prognosis. There was no sig-
niﬁcant diﬀerence between the two groups in terms of the
one-month mortality rate, which was 41.7% (35/84) in the
enterobacterial bacteremia group and 54.5% (6/11) in the
Aeromonas bacteremia group.
4. Discussion
Patients with liver cirrhosis are liable to suﬀer from bacterial
infection because of impaired function of the hepatic retic-
uloendothelial system and neutrophils, an inﬂux of bacteria
into the systemic circulation due to portal-caval shunts or a
decreased opsonic eﬀect in the ascites and the like [1, 3, 8].
The onset of bacterial infection in patients hospitalized with
liver cirrhosis is reported to be 30% to 60% [6, 9], and bac-
teremia has been reported as occurring in 3.5% to 8.8%
[2, 3, 10].
The infection focus is often unknown in bacteremia
of liver cirrhosis patients [1]. However, breakdown of the
intestinal mucosa and changes in the intestinal ﬂora, espe-
cially enterobacteria, as well as bacterial translocation to the
mesenteric lymph nodes from the bowel, are thought to
be involved in the onset of bacteremia and SBP [8]. Bac-
t e r i a lt r a n s l o c a t i o nh a sb e e nr e p o r t e dt ob ec o m m o ni np a -
tients with Child-Pugh class C cirrhosis [11], and it is easilyGastroenterology Research and Practice 3
Table 2: Comparison of background factors and clinical ﬁndings in the two groups.
Aeromonas bacteremia Enterobacterial bacteremia P value
Ages 61.2 ± 4.5 62.3 ± 10.8 P>0.05
Hepatocellular carcinoma 36.4% (4/11) 47.6% (40/84) P>0.05
Diabetes 27.3% (3/11) 28.6% (24/84) P>0.05
Ascites 100% (11/11) 90.5% (76/84) P>0.05
Diarrhea 9.1% (1/11) 4.8% (4/84) P>0.05
Shock (BP < 80mmHg) 36.4% (4/11) 15.5% (13/84) P>0.05
SBP 9.1% (1/11) 6.0% (5/84) P>0.05
Gastrointestinal bleeding
within 2 weeks 9.1% (1/11) 19.0% (16/84) P>0.05
SBP: spontaneous bacterial peritonitis.
Table 3: Comparison of laboratory ﬁndings in the two groups.
Aeromonas bacteremia Enterobacterial bacteremia P value
PT (%) 36.3 ± 15.9 42.7 ± 23.2 P>0.05
Albumin (g/dL) 2.40 ± 0.42 2.47 ± 0.49 P>0.05
T-bil. (mg/dL) 9.7 ± 6.4 7.8 ± 8.9 P>0.05
NH3 (µg/dL) 97 ± 37 89 ± 39 P>0.05
BUN (mg/dL) 27.1 ± 8.9 27.5 ± 9.7 P>0.05
Creatinine (mg/dL) 1.32 ± 0.55 1.36 ± 0.59 P>0.05
Child-Pugh score 13.3 ± 0.81 11.2 ± 1.93 P<0.01
MELD score 26.1 ± 1.86 21.9 ± 2.22 P<0.01
T-bil.: total bilirubin.
MELD: model for end-stage liver disease.
induced in animal models of severe liver disease [12]. In ad-
dition, in patients with liver cirrhosis, more severe hepatic
dysfunction is generally considered to be associated with
a higher rate of onset of bacteremia [1, 2], and patients
who develop bacteremia have a worse prognosis than cases
not complicated by bacteremia [1, 2, 5]. However, although
there have been reports comparing cases of SBP involving
Aeromonas sp. and other bacterial species [13], the present
report is the ﬁrst to describe a comparative study on Aer-
omonas bacteremia and bacteremia due to other bacterial
species in liver cirrhosis patients.
Aeromonas sp., which are Gram-negative, are found
throughout the natural world (in water and soil), and three
types—A. hydrophila, A. caviae,a n dA. veronii biovar sobria
(formerly known as A. sobria)—are pathogenic to humans
[14, 15]. Aeromonas bacteremia is rare in healthy people,
but is often found in cases of decompensated liver cirrhosis,
hematological malignancy, and hepatobiliary infection [14,
16–18], and has been quite well studied in Taiwan and
Republic of Korea among East Asian countries [2, 15–19].
The origin of the bacteremia in Aeromonas bacteremia with
decompensated liver cirrhosis is often unknown. In our
study, there were no patients in whom hepatobiliary infec-
tion appeared to be the focus of bacteremia in the Aeromonas
bacteremia group, although 2 out of 11 had gallstones.
Sources of Aeromonas infection include raw ﬁsh or un-
boiled water [14, 19]. The proportion of Aeromonas among
bacteremia cases in Japan is small, probably because of the
general availability of uncontaminated drinking water in
Japan, and because liver cirrhosis patients are advised not
to eat raw ﬁsh. Although Aeromonas bacteremia, along with
Vibrio sp. infection, tends to occur more frequently in the
summer [13, 15], the 11 cases of Aeromonas bacteremia in
this study reported no history of eating raw ﬁsh, or of skin
or soft tissue infection, and the incidence was not greater in
summer.
In this study, 90.9% (10/11) of the Aeromonas bacteremia
patients had severe liver cirrhosis with a Child-Pugh score of
13 or above, which was signiﬁcantly higher than the score in
enterobacterial bacteremia. Also, although Choi et al. found
no signiﬁcant diﬀerence in SBP cases, they reported a higher
number of Child-Pugh C cases with Aeromonas than with
other bacterial species [13], and the average Child-Pugh
score of Aeromonas bacteremia in the study by Ko et al. was
also 12 points or higher [18].
Moreover, the MELD score was also signiﬁcantly higher
in the Aeromonas bacteremia group than in the enterobac-
terial bacteremia group in our study. Therefore, Aeromonas
bacteremia may be more likely to arise in liver cirrhosis
patients with severe hepatic dysfunction.
Bacterial infection is involved in a quarter of mortalities
among cirrhosis patients [9, 20], and the mortality rate
among patients with complications arising from bacterial in-
fection is markedly higher [1, 21, 22]. Previous reports have
described short-term mortality rates of 27% to 60% in liver
cirrhosis complicated by bacteremia [1, 3, 4, 21], though4 Gastroenterology Research and Practice
slightly diﬀerent deﬁnitions of short-term mortality have
been employed. Recently, the mortality rate was reported to
be 42.2% among 1437 cirrhosis patients [21], and in our
study the overall mortality rate was 43.2% (41/95) in the two
groups combined.
It has been suggested that septic shock [13, 18] or the
onset of renal impairments, such as hepatorenal syndrome
[1, 23], plays an important role in determining the prognosis
of Aeromonas infection in liver cirrhosis. However, we found
no signiﬁcant diﬀerence in the short-term mortality rate,
renal dysfunction, and percentage of shock between the en-
terobacterial group and Aeromonas bacteremia group in this
study. Nevertheless, our results indicate that the severity of
liverdysfunctioninAeromonas-inducedbacteremiaisgreater
than that in enterobacteria-induced bacteremia in patients
with liver cirrhosis.
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